Actively Recruiting

Age: 18Years +
All Genders
NCT06762977

A Composite Assay for HER2-positive Early-stage Breast Cancer Management

Led by Fondazione IRCCS Istituto Nazionale dei Tumori, Milano · Updated on 2025-01-08

180

Participants Needed

2

Research Sites

89 weeks

Total Duration

On this page

Sponsors

F

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

Lead Sponsor

I

Istituto Nazionale Tumori IRCCS - Fondazione G. Pascale

Collaborating Sponsor

AI-Summary

What this Trial Is About

The goal of this observational study is to assess the prognostic value of a genomic classifier (S18) and its refined version (S\*) in women with early-stage HER2-positive breast cancer. The study aims to determine whether these tools can predict event-free (EFS) and disease-free survival (DFS) in patients treated with neoadjuvant and/or adjuvant trastuzumab-based therapies.

CONDITIONS

Official Title

A Composite Assay for HER2-positive Early-stage Breast Cancer Management

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Age 18 years or older
  • Operable breast cancer at stage I, II, or III
  • Any hormone receptor status in the primary tumor as per institutional guidelines
  • HER2-positive primary tumor confirmed by immunohistochemistry or ERBB2 gene amplification analysis
  • Received neoadjuvant and/or adjuvant therapy based on trastuzumab with or without pertuzumab
  • Provided written informed consent to participate
Not Eligible

You will not qualify if you...

  • Follow-up period less than 3 years after surgery
  • Prior diagnosis of invasive cancer before breast cancer diagnosis

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 2 locations

1

Ospedale Di Summa-Perrino

Brindisi, Italy, 72100

Actively Recruiting

2

Istituto Nazionale Tumori IRCCS - Fondazione G. Pascale

Naples, Italy, 80131

Actively Recruiting

Loading map...

Research Team

S

Serena Di Cosimo, MD, PhD

CONTACT

P

Paolo Verderio, PhD

CONTACT

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

0

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

A Composite Assay for HER2-positive Early-stage Breast Cancer Management | DecenTrialz